Item 8.01 Other Events.

On December 21, 2021, Arcus Biosciences, Inc. ("Arcus") and Gilead Sciences, Inc. ("Gilead") closed the previously announced amendment to their Option, License and Collaboration Agreement dated May 27, 2020. As a result, Gilead acquired rights to three Arcus programs-anti-TIGIT program (including domvanalimab and AB308), adenosine receptor antagonist program (including etrumadenant) and CD73 program (including quemliclustat). Gilead will pay to Arcus an aggregate of $725 million in option fees, which payment is expected early in the first quarter of 2022.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses